eli lilly glp-1 agonist is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating US approves new oral weight-loss
Description
Many of these drugs feature novel mechanisms of action or routes of administration and this increased competition may eventually exert downward pressure on pricing
The estimated half-life of tizepatide is approximately 116 h, supporting its once-weekly subcutaneous administration
Louis Health Care System
This content should not be taken as personal medical advice or a substitute for consultation with a qualified healthcare provider
3.4%, respectively) and headache (5.1% vs
